董事介绍
注:董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David A. Ricks | 男 | Chair, President and Chief Executive Officer | 57 | 2924.29万美元 | 75.73 | 2025-12-08 |
| Gabrielle Sulzberger | 女 | Director | 65 | 36.68万美元 | 未持股 | 2025-12-08 |
| Carolyn R. Bertozzi | 女 | Independent Director | 58 | 19.60万美元 | 未持股 | 2025-12-08 |
| Mary Lynne Hedley | 女 | Director | 62 | 33.90万美元 | 0.03 | 2025-12-08 |
| Kimberly H. Johnson | 女 | Director | 52 | 33.60万美元 | 未持股 | 2025-12-08 |
| Jon Moeller | 男 | Director | 60 | 0.99万美元 | 0.0071 | 2025-12-08 |
| J. Erik Fyrwald | 男 | Director | 65 | 34.67万美元 | 0.01 | 2025-12-08 |
| Ralph Alvarez | 男 | Director | 69 | 36.10万美元 | 未持股 | 2025-12-08 |
| Juan R. Luciano | 男 | Lead Independent Director | 63 | 39.80万美元 | 未持股 | 2025-12-08 |
| Katherine Baicker | 女 | Director | 53 | 36.10万美元 | 未持股 | 2025-12-08 |
| William G. Kaelin, Jr. | 男 | Director | 67 | 40.02万美元 | 未持股 | 2025-12-08 |
| Jamere Jackson | 男 | Director | 56 | 36.50万美元 | 未持股 | 2025-12-08 |
高管介绍
注:高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David A. Ricks | 男 | Chair, President and Chief Executive Officer | 57 | 2924.29万美元 | 75.73 | 2025-12-08 |
| Jacob Van Naarden | 男 | Executive Vice President and President, Lilly Oncology | 40 | 577.39万美元 | 2.82 | 2025-12-08 |
| Daniel Skovronsky | 男 | Executive Vice President, Chief Scientific Officer and President, Lilly Research Laboratories and Lilly Immunology | 51 | 1263.87万美元 | 21.23 | 2025-12-08 |
| Anne E. White | 女 | Executive Vice President and President, Lilly Neuroscience | 56 | 未披露 | 未持股 | 2025-12-08 |
| Anat Hakim | 女 | Executive Vice President, General Counsel and Secretary | 55 | 747.84万美元 | 4.35 | 2025-12-08 |
| Patrik Jonsson | 男 | Executive Vice President and President, Lilly Cardiometabolic Health and President, Lilly USA | 58 | 392.33万美元 | 未持股 | 2025-12-08 |
| Ilya Yuffa | 男 | Executive Vice President and President, Lilly International | 50 | 未披露 | 未持股 | 2025-12-08 |
| Edgardo Hernandez | 男 | Executive Vice President and President, Manufacturing Operations | 50 | 未披露 | 未持股 | 2025-12-08 |
| Diogo Rau | 男 | Executive Vice President and Chief Information and Digital Officer | 50 | 510.13万美元 | 未持股 | 2025-12-08 |
| Eric Dozier | 男 | Executive Vice President, Chief People Officer | 58 | 未披露 | 未持股 | 2025-12-08 |
| Lucas Montarce | 男 | Executive Vice President and Chief Financial Officer | 48 | 294.85万美元 | 1.40 | 2025-12-08 |
| Melissa Seymour | 女 | Executive Vice President, Global Quality | 55 | 未披露 | 未持股 | 2025-12-08 |
董事简历
中英对照 |  中文 |  英文- David A. Ricks
-
David A. Ricks,他是一名杰出的制药高管,自2017年以来担任Eli Lilly and Company的主席、总裁兼首席执行官,自1996年加入公司以来一直晋升。他在礼来公司的职业生涯涵盖了多个关键领导职位,包括礼来生物医药高级副总裁兼总裁(2012-2016),礼来美国公司总裁(2009-2012),以及礼来中国公司总裁兼总经理和礼来加拿大公司总经理等关键国际职位,他在全球市场上表现出卓越的领导力。Ricks作为国际药品制造商和协会联合会(IFPMA)和美国药物研究和制造商协会(PhRMA)的主任,在塑造制药行业方面发挥着重要作用。
David A. Ricks,is a distinguished pharmaceutical executive currently serving as Chair, President and Chief Executive Officer of Eli Lilly and Company since 2017, having risen through the ranks since joining the company in 1996. His career at Lilly spans key leadership positions including Senior Vice President and President of Lilly Bio-Medicines (2012-2016), President of Lilly USA (2009-2012), and pivotal international roles as President and General Manager of Lilly China and General Manager of Lilly Canada, where he demonstrated exceptional leadership in global markets. Ricks plays an influential role in shaping the pharmaceutical industry as Director of both the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Pharmaceutical Research and Manufacturers of America (PhRMA). - David A. Ricks,他是一名杰出的制药高管,自2017年以来担任Eli Lilly and Company的主席、总裁兼首席执行官,自1996年加入公司以来一直晋升。他在礼来公司的职业生涯涵盖了多个关键领导职位,包括礼来生物医药高级副总裁兼总裁(2012-2016),礼来美国公司总裁(2009-2012),以及礼来中国公司总裁兼总经理和礼来加拿大公司总经理等关键国际职位,他在全球市场上表现出卓越的领导力。Ricks作为国际药品制造商和协会联合会(IFPMA)和美国药物研究和制造商协会(PhRMA)的主任,在塑造制药行业方面发挥着重要作用。
- David A. Ricks,is a distinguished pharmaceutical executive currently serving as Chair, President and Chief Executive Officer of Eli Lilly and Company since 2017, having risen through the ranks since joining the company in 1996. His career at Lilly spans key leadership positions including Senior Vice President and President of Lilly Bio-Medicines (2012-2016), President of Lilly USA (2009-2012), and pivotal international roles as President and General Manager of Lilly China and General Manager of Lilly Canada, where he demonstrated exceptional leadership in global markets. Ricks plays an influential role in shaping the pharmaceutical industry as Director of both the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Pharmaceutical Research and Manufacturers of America (PhRMA).
- Gabrielle Sulzberger
-
Gabrielle Sulzberger自2003年起担任公司的董事。Sulzberger女士担任一个多元化投资基金,Rustic Canyon/Fontis Partners, LP的负责人(2005年10月公司成立起担任此职位)。另外,Sulzberger女士担任Villanueva公司(Villanueva Companies,一家私人持股公司,拥有多元化的投资利益)担任财务总监(2002-2005年)。Sulzberger女士也在Stage Stores股份有限公司(Stage Stores, Inc.)和Brixmor Property Group股份有限公司(Brixmor Property Group Inc.)董事会工作。
Gabrielle Sulzberger,is a distinguished investment professional and corporate advisor currently serving as Senior Managing Director at Centerbridge Partners (2024–present), where she previously acted as Senior Advisor (2021–2024). She concurrently holds a Senior Advisor role at Teneo (2024–present), having chaired its Global ESG Advisory practice (2021–2024). Her extensive advisory experience includes serving as Senior Advisor at Two Sigma Impact (2021–2023) and earlier as General Partner at Rustic Canyon/Fontis Partners (2005–2018). A respected corporate director, Sulzberger previously chaired the board and audit committee of Whole Foods Market, Inc. - Gabrielle Sulzberger自2003年起担任公司的董事。Sulzberger女士担任一个多元化投资基金,Rustic Canyon/Fontis Partners, LP的负责人(2005年10月公司成立起担任此职位)。另外,Sulzberger女士担任Villanueva公司(Villanueva Companies,一家私人持股公司,拥有多元化的投资利益)担任财务总监(2002-2005年)。Sulzberger女士也在Stage Stores股份有限公司(Stage Stores, Inc.)和Brixmor Property Group股份有限公司(Brixmor Property Group Inc.)董事会工作。
- Gabrielle Sulzberger,is a distinguished investment professional and corporate advisor currently serving as Senior Managing Director at Centerbridge Partners (2024–present), where she previously acted as Senior Advisor (2021–2024). She concurrently holds a Senior Advisor role at Teneo (2024–present), having chaired its Global ESG Advisory practice (2021–2024). Her extensive advisory experience includes serving as Senior Advisor at Two Sigma Impact (2021–2023) and earlier as General Partner at Rustic Canyon/Fontis Partners (2005–2018). A respected corporate director, Sulzberger previously chaired the board and audit committee of Whole Foods Market, Inc.
- Carolyn R. Bertozzi
-
Carolyn R. Bertozzi,斯坦福大学,Anne T。和Robert M. Bass化学教授,化学和系统生物学和放射学教授,礼貌2015至今; Howard Hughes医学研究所,研究员(2000年至今);加州大学,伯克利,TZ 和Irmgard Chu化学教授和分子与细胞生物学教授(1996年至2015年)。
Carolyn R. Bertozzi,has served as the Anne T. and Robert M. Bass Professor of Chemistry at Stanford University since 2015 and as the Baker Family Director of Stanford's Sarafan ChEM-H Institute since 2021. Since 2000, Dr. Bertozzi has also served as an Investigator at the Howard Hughes Medical Institute. From 1996 to 2015, she was a professor of Chemistry and Molecular and Cell Biology at the University of California, Berkeley. Dr. Bertozzi was jointly awarded the 2022 Nobel Prize in Chemistry and the 2022 Wolf Prize in Chemistry. She is a member of the National Academy of Sciences, the National Academy of Medicine and National Academy of Inventors, as well as the Royal Society (UK), Accademia Nazionale dei Lincei and the German Academy of Sciences Leopoldina.Dr. Bertozzi also serves as a director of OmniAb, Inc. and previously served as a director of Eli Lilly and Company. - Carolyn R. Bertozzi,斯坦福大学,Anne T。和Robert M. Bass化学教授,化学和系统生物学和放射学教授,礼貌2015至今; Howard Hughes医学研究所,研究员(2000年至今);加州大学,伯克利,TZ 和Irmgard Chu化学教授和分子与细胞生物学教授(1996年至2015年)。
- Carolyn R. Bertozzi,has served as the Anne T. and Robert M. Bass Professor of Chemistry at Stanford University since 2015 and as the Baker Family Director of Stanford's Sarafan ChEM-H Institute since 2021. Since 2000, Dr. Bertozzi has also served as an Investigator at the Howard Hughes Medical Institute. From 1996 to 2015, she was a professor of Chemistry and Molecular and Cell Biology at the University of California, Berkeley. Dr. Bertozzi was jointly awarded the 2022 Nobel Prize in Chemistry and the 2022 Wolf Prize in Chemistry. She is a member of the National Academy of Sciences, the National Academy of Medicine and National Academy of Inventors, as well as the Royal Society (UK), Accademia Nazionale dei Lincei and the German Academy of Sciences Leopoldina.Dr. Bertozzi also serves as a director of OmniAb, Inc. and previously served as a director of Eli Lilly and Company.
- Mary Lynne Hedley
-
Mary Lynne Hedley,她于2021年2月加入Centessa Pharmaceuticals Plc董事会。Hedley博士还担任Broad Institute的高级研究员和战略顾问。从2010年到2020年,Hedley博士曾担任TESARO(她也是共同创立的生物技术公司)的董事、总裁兼首席运营官。在被Glaxo Smith Kline(GSK)收购之前,TESARO已经从风险投资和公众投资者那里获得了20亿美元的资金,在美国和欧洲发展到约900名员工,并获得了FDA和欧洲监管机构的多种药物批准。TESARO被认为是一家激烈的公司,拥有一系列处于早期和晚期开发阶段的候选药物,随着药物Zejula的商业化推出,改变了女性卵巢癌的治疗模式。在成立TESARO之前,Mary Lynne是Abraxis Bioscience的执行副总裁兼首席科学官,负责研发、运营、医疗事务和业务发展。在加入Abraxis之前,她曾担任日本制药公司Eisai Inc.的执行副总裁,她在2008年1月被Eisai以39亿美元收购MGI PHARMA后担任该职位。她于1983年获得Purdue University微生物学学士学位,并于1988年获得UT Southwestern, Dallas的免疫学博士学位。
Mary Lynne Hedley,joined board of directors in February 2021. Dr. Hedley also serves as a Senior Scientific Fellow and strategic advisor to the Broad Institute of MIT and Harvard and a venture partner at Third Rock Ventures. Dr. Hedley also sits on the board of directors for Veeva Systems (Nasdaq: VEEV) and Eli Lilly and Company. Dr. Hedley previously served as Director, President and Chief Operating Officer of TESARO, a biotechnology company she also co-founded, from 2010 until 2019. Prior to its acquisition by Glaxo Smith Kline (GSK), TESARO had secured $2 billion of funding from venture and public investors, grew to approximately 900 employees in the U.S. and Europe and had received multiple drug approvals from FDA and European regulatory authorities. TESARO was recognized as a Fierce 15 Company, had a pipeline of medicine candidates in early and late stage development and with the commercial launch of the medicines Zejula, changed the treatment paradigm for women diagnosed with ovarian cancer. Prior to founding TESARO, Dr. Hedley was Executive Vice President and Chief Scientific Officer of Abraxis Bioscience, responsible for R&D, Operations, Medical Affairs and Business Development. Prior to joining Abraxis, she served as Executive Vice President of the Japanese Pharmaceutical company Eisai Inc, a role she assumed following the acquisition in January 2008, of MGI PHARMA by Eisai for $3.9 Billion. Dr. Hedley received a B.S. in Microbiology from Purdue University in 1983 and a Ph.D. in Immunology from UT Southwestern, Dallas in 1988. - Mary Lynne Hedley,她于2021年2月加入Centessa Pharmaceuticals Plc董事会。Hedley博士还担任Broad Institute的高级研究员和战略顾问。从2010年到2020年,Hedley博士曾担任TESARO(她也是共同创立的生物技术公司)的董事、总裁兼首席运营官。在被Glaxo Smith Kline(GSK)收购之前,TESARO已经从风险投资和公众投资者那里获得了20亿美元的资金,在美国和欧洲发展到约900名员工,并获得了FDA和欧洲监管机构的多种药物批准。TESARO被认为是一家激烈的公司,拥有一系列处于早期和晚期开发阶段的候选药物,随着药物Zejula的商业化推出,改变了女性卵巢癌的治疗模式。在成立TESARO之前,Mary Lynne是Abraxis Bioscience的执行副总裁兼首席科学官,负责研发、运营、医疗事务和业务发展。在加入Abraxis之前,她曾担任日本制药公司Eisai Inc.的执行副总裁,她在2008年1月被Eisai以39亿美元收购MGI PHARMA后担任该职位。她于1983年获得Purdue University微生物学学士学位,并于1988年获得UT Southwestern, Dallas的免疫学博士学位。
- Mary Lynne Hedley,joined board of directors in February 2021. Dr. Hedley also serves as a Senior Scientific Fellow and strategic advisor to the Broad Institute of MIT and Harvard and a venture partner at Third Rock Ventures. Dr. Hedley also sits on the board of directors for Veeva Systems (Nasdaq: VEEV) and Eli Lilly and Company. Dr. Hedley previously served as Director, President and Chief Operating Officer of TESARO, a biotechnology company she also co-founded, from 2010 until 2019. Prior to its acquisition by Glaxo Smith Kline (GSK), TESARO had secured $2 billion of funding from venture and public investors, grew to approximately 900 employees in the U.S. and Europe and had received multiple drug approvals from FDA and European regulatory authorities. TESARO was recognized as a Fierce 15 Company, had a pipeline of medicine candidates in early and late stage development and with the commercial launch of the medicines Zejula, changed the treatment paradigm for women diagnosed with ovarian cancer. Prior to founding TESARO, Dr. Hedley was Executive Vice President and Chief Scientific Officer of Abraxis Bioscience, responsible for R&D, Operations, Medical Affairs and Business Development. Prior to joining Abraxis, she served as Executive Vice President of the Japanese Pharmaceutical company Eisai Inc, a role she assumed following the acquisition in January 2008, of MGI PHARMA by Eisai for $3.9 Billion. Dr. Hedley received a B.S. in Microbiology from Purdue University in 1983 and a Ph.D. in Immunology from UT Southwestern, Dallas in 1988.
- Kimberly H. Johnson
-
Kimberly H. Johnson,2018年到至今担任联邦国民抵押贷款协会Fannie Mae,美国可负担抵押贷款融资提供公司的执行副总裁兼首席运营官,执行副总裁兼首席风险官(2017-2018年),高级副总裁兼首席风险官(2015-2017年),高级副总裁兼副首席风险官(2013-2015年)。Credit Suisse AG,一家成立于瑞士的全球财富管理、投资银行和金融服务公司,利率衍生产品总监(2005-2006年),副总裁(2002-2004年)。
Kimberly H. Johnson,is a seasoned financial executive currently serving as Vice President and Chief Operating Officer at T. Rowe Price Group, Inc., where she leads operational strategy for the global asset management firm since 2022. Prior to this role, she spent nine years at Federal National Mortgage Association (Fannie Mae), ascending through progressively senior positions including Executive Vice President and Chief Operating Officer (2018-2022), Chief Risk Officer (2015-2018), and Deputy Chief Risk Officer (2013-2015), where she strengthened the enterprise's risk management capabilities and operational infrastructure. Earlier in her career, Johnson served as Director of Interest Rate Derivative Products at Credit Suisse AG (2005-2006). - Kimberly H. Johnson,2018年到至今担任联邦国民抵押贷款协会Fannie Mae,美国可负担抵押贷款融资提供公司的执行副总裁兼首席运营官,执行副总裁兼首席风险官(2017-2018年),高级副总裁兼首席风险官(2015-2017年),高级副总裁兼副首席风险官(2013-2015年)。Credit Suisse AG,一家成立于瑞士的全球财富管理、投资银行和金融服务公司,利率衍生产品总监(2005-2006年),副总裁(2002-2004年)。
- Kimberly H. Johnson,is a seasoned financial executive currently serving as Vice President and Chief Operating Officer at T. Rowe Price Group, Inc., where she leads operational strategy for the global asset management firm since 2022. Prior to this role, she spent nine years at Federal National Mortgage Association (Fannie Mae), ascending through progressively senior positions including Executive Vice President and Chief Operating Officer (2018-2022), Chief Risk Officer (2015-2018), and Deputy Chief Risk Officer (2013-2015), where she strengthened the enterprise's risk management capabilities and operational infrastructure. Earlier in her career, Johnson served as Director of Interest Rate Derivative Products at Credit Suisse AG (2005-2006).
- Jon Moeller
-
Jon Moeller,是宝洁(P & G)的董事会主席、总裁兼首席执行官。作为二十多年来宝洁领导团队不可或缺的一部分,Moeller先生是一位强有力的领导者。他曾在财务、业务和战略职能部门担任重要职务,担任副董事长、首席财务官和首席运营官,负责公司发展中市场和全球运营。他还担任商业圆桌会议、消费品论坛和Catalyst的董事会成员,这是一家通过工作场所包容加速女性进步的全球非营利组织。
Jon Moeller,is a seasoned corporate leader who currently serves as Chairman, President and Chief Executive Officer of Procter & Gamble Company, having assumed the chairman role in 2022 after serving as President and CEO since 2021. His distinguished 13-year tenure in P&G's executive leadership includes serving as Vice Chairman, Chief Financial Officer and Chief Operating Officer (2019-2021), Vice Chairman and Chief Financial Officer (2017-2019), and Chief Financial Officer (2009-2017). - Jon Moeller,是宝洁(P & G)的董事会主席、总裁兼首席执行官。作为二十多年来宝洁领导团队不可或缺的一部分,Moeller先生是一位强有力的领导者。他曾在财务、业务和战略职能部门担任重要职务,担任副董事长、首席财务官和首席运营官,负责公司发展中市场和全球运营。他还担任商业圆桌会议、消费品论坛和Catalyst的董事会成员,这是一家通过工作场所包容加速女性进步的全球非营利组织。
- Jon Moeller,is a seasoned corporate leader who currently serves as Chairman, President and Chief Executive Officer of Procter & Gamble Company, having assumed the chairman role in 2022 after serving as President and CEO since 2021. His distinguished 13-year tenure in P&G's executive leadership includes serving as Vice Chairman, Chief Financial Officer and Chief Operating Officer (2019-2021), Vice Chairman and Chief Financial Officer (2017-2019), and Chief Financial Officer (2009-2017).
- J. Erik Fyrwald
-
J. Erik Fyrwald,自2024年2月6日起担任首席执行官、董事会成员。他从先正达加入International Flavors & Fragrances Inc.,自2016年起担任首席执行官。在任职先正达之前,Fyrwald先生于2012年5月至2016年5月期间担任Univar Solutions的首席执行官,于2008年至2011年期间担任纳尔科的董事长兼首席执行官,在纳尔科与艺康集团公司合并后,他担任艺康的总裁。Fyrwald先生的职业生涯始于1981年的杜邦公司。Fyrwald先生在杜邦27年期间担任过多个职位,包括E.I. du Pont de Nemours and Company农业和营养部门的集团副总裁以及杜邦营养和健康业务的副总裁兼总经理。Fyrwald先生就读于特拉华大学,并于1981年获得化学工程理学学士学位。他还于1998年在哈佛商学院完成了高级管理课程。
J. Erik Fyrwald,is an accomplished global business leader currently serving as Chief Executive Officer of International Flavors & Fragrances Inc. (IFF) and Member of its Board of Directors since 2024. With over four decades of executive experience in chemicals, agriculture, and industrial sectors, Fyrwald previously led Syngenta Group as President and CEO (2016-2023), where he also served on the Board of Directors and Sustainability Committee. His distinguished career includes serving as President and CEO of Univar, Inc. (2012-2016), President of Ecolab, Inc. (2011-2012), and Chairman and CEO of Nalco Company (2008-2011). Fyrwald began his career at DuPont, where he held progressive leadership roles over 28 years (1980-2008), culminating as Group Vice President of Agriculture and Nutrition. - J. Erik Fyrwald,自2024年2月6日起担任首席执行官、董事会成员。他从先正达加入International Flavors & Fragrances Inc.,自2016年起担任首席执行官。在任职先正达之前,Fyrwald先生于2012年5月至2016年5月期间担任Univar Solutions的首席执行官,于2008年至2011年期间担任纳尔科的董事长兼首席执行官,在纳尔科与艺康集团公司合并后,他担任艺康的总裁。Fyrwald先生的职业生涯始于1981年的杜邦公司。Fyrwald先生在杜邦27年期间担任过多个职位,包括E.I. du Pont de Nemours and Company农业和营养部门的集团副总裁以及杜邦营养和健康业务的副总裁兼总经理。Fyrwald先生就读于特拉华大学,并于1981年获得化学工程理学学士学位。他还于1998年在哈佛商学院完成了高级管理课程。
- J. Erik Fyrwald,is an accomplished global business leader currently serving as Chief Executive Officer of International Flavors & Fragrances Inc. (IFF) and Member of its Board of Directors since 2024. With over four decades of executive experience in chemicals, agriculture, and industrial sectors, Fyrwald previously led Syngenta Group as President and CEO (2016-2023), where he also served on the Board of Directors and Sustainability Committee. His distinguished career includes serving as President and CEO of Univar, Inc. (2012-2016), President of Ecolab, Inc. (2011-2012), and Chairman and CEO of Nalco Company (2008-2011). Fyrwald began his career at DuPont, where he held progressive leadership roles over 28 years (1980-2008), culminating as Group Vice President of Agriculture and Nutrition.
- Ralph Alvarez
-
Ralph Alvarez于2013年至今在加州风洋食馆担任执行董事长职务。加州风洋食馆是一家主要在日本经营的餐馆运营公司。自2006年至2009年期间内,他在麦当劳连锁速食店担任总裁兼首席运营官。他还在以下公司和组织任职:迈阿密大学、总裁委员会、工商管理学院董事会监督部和国际顾问委员会。他也在以下公共公司董事会任职:劳氏公司、敦肯布兰德集团、Realogy控股公司。他也在加州风洋食馆董事会任职,加州风洋食馆是一家私人公司。在此之前,他在麦当劳连锁速食店和科凯国际集团董事会任职。
Ralph Alvarez,is a seasoned executive with an impressive career spanning leadership roles in global private equity and the food service industry. Currently serving as Operating Partner at Advent International Corporation, a leading global private equity firm (2017–present). Previously, he was Chairman of the Board at Skylark Co., Ltd., a top restaurant operator in Japan (2013–2018), and held key roles at McDonald's Corporation, including President and Chief Operating Officer (2006–2009). Beyond his professional achievements, Alvarez contributes as a member of the University of Miami President's Council, demonstrating his commitment to education and leadership development. - Ralph Alvarez于2013年至今在加州风洋食馆担任执行董事长职务。加州风洋食馆是一家主要在日本经营的餐馆运营公司。自2006年至2009年期间内,他在麦当劳连锁速食店担任总裁兼首席运营官。他还在以下公司和组织任职:迈阿密大学、总裁委员会、工商管理学院董事会监督部和国际顾问委员会。他也在以下公共公司董事会任职:劳氏公司、敦肯布兰德集团、Realogy控股公司。他也在加州风洋食馆董事会任职,加州风洋食馆是一家私人公司。在此之前,他在麦当劳连锁速食店和科凯国际集团董事会任职。
- Ralph Alvarez,is a seasoned executive with an impressive career spanning leadership roles in global private equity and the food service industry. Currently serving as Operating Partner at Advent International Corporation, a leading global private equity firm (2017–present). Previously, he was Chairman of the Board at Skylark Co., Ltd., a top restaurant operator in Japan (2013–2018), and held key roles at McDonald's Corporation, including President and Chief Operating Officer (2006–2009). Beyond his professional achievements, Alvarez contributes as a member of the University of Miami President's Council, demonstrating his commitment to education and leadership development.
- Juan R. Luciano
-
Juan R. Luciano,是一位杰出的企业领导者,目前自2015年起担任阿彻丹尼尔斯米德兰公司(TERM1)的主席、首席执行官兼总裁,此前曾担任总裁兼首席运营官(2014-2015年),负责监管这家全球食品加工和商品贸易巨头。在加入ADM之前,他是陶氏化学公司执行副总裁兼性能部门总裁(2010-2011年)。除了担任高管职务,卢西亚诺还作为丰益国际的候补董事和Intersect Illinois的董事为公司治理做出贡献,同时还在Rush System董事会任职。
Juan R. Luciano,is a distinguished corporate leader currently serving as Chair, Chief Executive Officer, and President of Archer-Daniels-Midland Company (ADM) since 2015, having previously held the roles of President and Chief Operating Officer (2014-2015), where he oversees the global food processing and commodities-trading giant. Prior to ADM, he was Executive Vice President and President of the Performance Division at The Dow Chemical Company (2010-2011). Beyond his executive roles, Luciano contributes to corporate governance as an alternate director of Wilmar International and a director of Intersect Illinois, while also serving on the Rush System Board of Directors. - Juan R. Luciano,是一位杰出的企业领导者,目前自2015年起担任阿彻丹尼尔斯米德兰公司(TERM1)的主席、首席执行官兼总裁,此前曾担任总裁兼首席运营官(2014-2015年),负责监管这家全球食品加工和商品贸易巨头。在加入ADM之前,他是陶氏化学公司执行副总裁兼性能部门总裁(2010-2011年)。除了担任高管职务,卢西亚诺还作为丰益国际的候补董事和Intersect Illinois的董事为公司治理做出贡献,同时还在Rush System董事会任职。
- Juan R. Luciano,is a distinguished corporate leader currently serving as Chair, Chief Executive Officer, and President of Archer-Daniels-Midland Company (ADM) since 2015, having previously held the roles of President and Chief Operating Officer (2014-2015), where he oversees the global food processing and commodities-trading giant. Prior to ADM, he was Executive Vice President and President of the Performance Division at The Dow Chemical Company (2010-2011). Beyond his executive roles, Luciano contributes to corporate governance as an alternate director of Wilmar International and a director of Intersect Illinois, while also serving on the Rush System Board of Directors.
- Katherine Baicker
-
Katherine Baicker ,Harris 公共政策学院,芝加哥大学院长和 Emmett Dedmon 教授 2017 年至今。Harvard T.H. Chan 公共卫生学院,卫生政策与管理系 C. Boyden Gray 教授 (2014 - 2017) 代理主席 (2014 - 2016) 卫生经济学教授 (2007 - 2017)。总裁办公厅经济顾问委员会成员 (2005 - 2007) 高级经济学家 (2001 - 2002)。
Katherine Baicker,is a distinguished economist and academic leader currently serving as Provost of the University of Chicago (2023–present) and Emmett Dedmon Professor at the Harris School of Public Policy (2017–present), where she previously served as Dean (2017–2023). Prior to joining the University of Chicago, she was the C. Boyden Gray Professor of Health Economics at Harvard University (2014–2017), where she also chaired the Department of Health Policy and Management (2014–2016) with joint appointments at the Harvard T.H. Chan School of Public Health and Harvard Kennedy School of Government. A Research Associate at the National Bureau of Economic Research since 2007, Baicker has also held significant public policy roles, including serving as a Senate-confirmed Member of the White House Council of Economic Advisers (2005–2007). - Katherine Baicker ,Harris 公共政策学院,芝加哥大学院长和 Emmett Dedmon 教授 2017 年至今。Harvard T.H. Chan 公共卫生学院,卫生政策与管理系 C. Boyden Gray 教授 (2014 - 2017) 代理主席 (2014 - 2016) 卫生经济学教授 (2007 - 2017)。总裁办公厅经济顾问委员会成员 (2005 - 2007) 高级经济学家 (2001 - 2002)。
- Katherine Baicker,is a distinguished economist and academic leader currently serving as Provost of the University of Chicago (2023–present) and Emmett Dedmon Professor at the Harris School of Public Policy (2017–present), where she previously served as Dean (2017–2023). Prior to joining the University of Chicago, she was the C. Boyden Gray Professor of Health Economics at Harvard University (2014–2017), where she also chaired the Department of Health Policy and Management (2014–2016) with joint appointments at the Harvard T.H. Chan School of Public Health and Harvard Kennedy School of Government. A Research Associate at the National Bureau of Economic Research since 2007, Baicker has also held significant public policy roles, including serving as a Senate-confirmed Member of the White House Council of Economic Advisers (2005–2007).
- William G. Kaelin, Jr.
-
William G. Kaelin, Jr.于2002年至今在达纳—法勃尔/哈佛大学癌症中心担任医药学教授。自2009年至今他在基础科学部门担任副主任。他还在以下公司任职:美国医学研究所、美国国家科学院和美国医师协会。他获得了加拿大Gairdner国际奖项及法国研究所Lefoulon-Delalande奖。
William G. Kaelin, Jr.,is a Nobel Prize-winning physician-scientist who currently holds the prestigious Sidney Farber Professorship of Medicine at Harvard Medical School (2018-present), where he previously served as Professor of Medicine (2002-2018). A leading researcher at Dana-Farber Cancer Institute since 2002, he has also been an Investigator at the Howard Hughes Medical Institute since 2002, following his tenure as Assistant Investigator (1998-2002). Dr. Kaelin's groundbreaking work earned him the 2019 Nobel Prize in Physiology or Medicine, along with other distinguished honors including the Albert Lasker Basic Medical Research Award, Canada Gairdner International Award, Wiley Prize in Biomedical Sciences, and Paul Marks Prize for Cancer Research. - William G. Kaelin, Jr.于2002年至今在达纳—法勃尔/哈佛大学癌症中心担任医药学教授。自2009年至今他在基础科学部门担任副主任。他还在以下公司任职:美国医学研究所、美国国家科学院和美国医师协会。他获得了加拿大Gairdner国际奖项及法国研究所Lefoulon-Delalande奖。
- William G. Kaelin, Jr.,is a Nobel Prize-winning physician-scientist who currently holds the prestigious Sidney Farber Professorship of Medicine at Harvard Medical School (2018-present), where he previously served as Professor of Medicine (2002-2018). A leading researcher at Dana-Farber Cancer Institute since 2002, he has also been an Investigator at the Howard Hughes Medical Institute since 2002, following his tenure as Assistant Investigator (1998-2002). Dr. Kaelin's groundbreaking work earned him the 2019 Nobel Prize in Physiology or Medicine, along with other distinguished honors including the Albert Lasker Basic Medical Research Award, Canada Gairdner International Award, Wiley Prize in Biomedical Sciences, and Paul Marks Prize for Cancer Research.
- Jamere Jackson
-
Jamere Jackson于2020年9月被任命为首席财务官,并以该身份领导财务和门店发展团队。在加入AutoZone之前,Jackson先生自2018年起担任全球租赁公司Hertz Global Holdings, Inc.的执行副总裁兼首席财务官。2014年至2018年,Jackson先生在信息、数据和测量公司尼尔森担任首席财务官。在2014年之前,Jackson先生曾在通用电气公司担任过多种领导职务,包括通用电气石油和天然气部门的副总裁兼首席财务官。Jackson先生在礼来公司董事会任职。
Jamere Jackson was named Chief Financial Officer in September 2020 and, in that capacity, leads the Finance and Store Development teams. Prior to joining AutoZone, Mr. Jackson served as Executive Vice President and Chief Financial Officer of Hertz Global Holdings, Inc., a global rental company, from 2018 to 2020. From 2014 to 2018, Mr. Jackson served as Chief Financial Officer of Nielsen Holdings plc, an information, data and measurement company. Prior to 2014, Mr. Jackson held a variety of leadership roles at General Electric Company, including Vice President and Chief Financial Officer of a division of General Electric Oil and Gas. Mr. Jackson serves on the Board of Directors for Eli Lilly & Co. - Jamere Jackson于2020年9月被任命为首席财务官,并以该身份领导财务和门店发展团队。在加入AutoZone之前,Jackson先生自2018年起担任全球租赁公司Hertz Global Holdings, Inc.的执行副总裁兼首席财务官。2014年至2018年,Jackson先生在信息、数据和测量公司尼尔森担任首席财务官。在2014年之前,Jackson先生曾在通用电气公司担任过多种领导职务,包括通用电气石油和天然气部门的副总裁兼首席财务官。Jackson先生在礼来公司董事会任职。
- Jamere Jackson was named Chief Financial Officer in September 2020 and, in that capacity, leads the Finance and Store Development teams. Prior to joining AutoZone, Mr. Jackson served as Executive Vice President and Chief Financial Officer of Hertz Global Holdings, Inc., a global rental company, from 2018 to 2020. From 2014 to 2018, Mr. Jackson served as Chief Financial Officer of Nielsen Holdings plc, an information, data and measurement company. Prior to 2014, Mr. Jackson held a variety of leadership roles at General Electric Company, including Vice President and Chief Financial Officer of a division of General Electric Oil and Gas. Mr. Jackson serves on the Board of Directors for Eli Lilly & Co.
高管简历
中英对照 |  中文 |  英文- David A. Ricks
David A. Ricks,他是一名杰出的制药高管,自2017年以来担任Eli Lilly and Company的主席、总裁兼首席执行官,自1996年加入公司以来一直晋升。他在礼来公司的职业生涯涵盖了多个关键领导职位,包括礼来生物医药高级副总裁兼总裁(2012-2016),礼来美国公司总裁(2009-2012),以及礼来中国公司总裁兼总经理和礼来加拿大公司总经理等关键国际职位,他在全球市场上表现出卓越的领导力。Ricks作为国际药品制造商和协会联合会(IFPMA)和美国药物研究和制造商协会(PhRMA)的主任,在塑造制药行业方面发挥着重要作用。
David A. Ricks,is a distinguished pharmaceutical executive currently serving as Chair, President and Chief Executive Officer of Eli Lilly and Company since 2017, having risen through the ranks since joining the company in 1996. His career at Lilly spans key leadership positions including Senior Vice President and President of Lilly Bio-Medicines (2012-2016), President of Lilly USA (2009-2012), and pivotal international roles as President and General Manager of Lilly China and General Manager of Lilly Canada, where he demonstrated exceptional leadership in global markets. Ricks plays an influential role in shaping the pharmaceutical industry as Director of both the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Pharmaceutical Research and Manufacturers of America (PhRMA).- David A. Ricks,他是一名杰出的制药高管,自2017年以来担任Eli Lilly and Company的主席、总裁兼首席执行官,自1996年加入公司以来一直晋升。他在礼来公司的职业生涯涵盖了多个关键领导职位,包括礼来生物医药高级副总裁兼总裁(2012-2016),礼来美国公司总裁(2009-2012),以及礼来中国公司总裁兼总经理和礼来加拿大公司总经理等关键国际职位,他在全球市场上表现出卓越的领导力。Ricks作为国际药品制造商和协会联合会(IFPMA)和美国药物研究和制造商协会(PhRMA)的主任,在塑造制药行业方面发挥着重要作用。
- David A. Ricks,is a distinguished pharmaceutical executive currently serving as Chair, President and Chief Executive Officer of Eli Lilly and Company since 2017, having risen through the ranks since joining the company in 1996. His career at Lilly spans key leadership positions including Senior Vice President and President of Lilly Bio-Medicines (2012-2016), President of Lilly USA (2009-2012), and pivotal international roles as President and General Manager of Lilly China and General Manager of Lilly Canada, where he demonstrated exceptional leadership in global markets. Ricks plays an influential role in shaping the pharmaceutical industry as Director of both the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Pharmaceutical Research and Manufacturers of America (PhRMA).
- Jacob Van Naarden
Jacob Van Naarden,自2015年12月起担任Loxo Oncology, Inc.首席商务官,自2014年5月担任Loxo Oncology, Inc.开发战略部副总裁。加入Loxo Oncology前,2013年7月至2014年5月,Mr. Van Naarden曾担任HealthCor Management分析师。2008年8月至2013年6月,Mr. Van Naarden曾在Aisling Capital任职,一开始担任分析师后担任助理一职。2006年7月,Mr. Van Naarden在Goldman Sachs开始他的职业生涯直至2008年6月。 Mr. Van Naarden获得了Princeton University分子生物学学士学位。
Jacob Van Naarden,Executive Vice President and President, Lilly Oncology (since 2021). Previously, Mr. Van Naarden served as chief executive officer-Loxo Oncology at Lilly, and chief operating officer-Loxo Oncology at Lilly. Mr. Van Naarden joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer. In previous roles, Mr. Van Naarden worked in various biotechnology investing, operating, and advisory capacities, including positions with HealthCor Management, Aisling Capital, and Goldman Sachs. Mr. Van Naarden has six years of service with Lilly.- Jacob Van Naarden,自2015年12月起担任Loxo Oncology, Inc.首席商务官,自2014年5月担任Loxo Oncology, Inc.开发战略部副总裁。加入Loxo Oncology前,2013年7月至2014年5月,Mr. Van Naarden曾担任HealthCor Management分析师。2008年8月至2013年6月,Mr. Van Naarden曾在Aisling Capital任职,一开始担任分析师后担任助理一职。2006年7月,Mr. Van Naarden在Goldman Sachs开始他的职业生涯直至2008年6月。 Mr. Van Naarden获得了Princeton University分子生物学学士学位。
- Jacob Van Naarden,Executive Vice President and President, Lilly Oncology (since 2021). Previously, Mr. Van Naarden served as chief executive officer-Loxo Oncology at Lilly, and chief operating officer-Loxo Oncology at Lilly. Mr. Van Naarden joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer. In previous roles, Mr. Van Naarden worked in various biotechnology investing, operating, and advisory capacities, including positions with HealthCor Management, Aisling Capital, and Goldman Sachs. Mr. Van Naarden has six years of service with Lilly.
- Daniel Skovronsky
Daniel Skovronsky,科学与技术高级副总裁兼礼来研究实验室总裁,于2018年6月生效。2010年加入公司之前,Skovronsky博士是Avid Radiopharmaceutical公司的首席执行官和创始人。
Daniel Skovronsky,Executive Vice President, Chief Scientific Officer and President, Lilly Research Laboratories and Lilly Immunology (since 2024). Prior to assuming his current role, Dr. Skovronsky served as Executive Vice President, Chief Scientific and Medical Officer, and President, Lilly Research Laboratories since 2018. Dr. Skovronsky has held other leadership roles with Lilly, including as senior vice president, clinical and product development and vice president, diabetes research. Dr. Skovronsky has 14 years of service with Lilly.- Daniel Skovronsky,科学与技术高级副总裁兼礼来研究实验室总裁,于2018年6月生效。2010年加入公司之前,Skovronsky博士是Avid Radiopharmaceutical公司的首席执行官和创始人。
- Daniel Skovronsky,Executive Vice President, Chief Scientific Officer and President, Lilly Research Laboratories and Lilly Immunology (since 2024). Prior to assuming his current role, Dr. Skovronsky served as Executive Vice President, Chief Scientific and Medical Officer, and President, Lilly Research Laboratories since 2018. Dr. Skovronsky has held other leadership roles with Lilly, including as senior vice president, clinical and product development and vice president, diabetes research. Dr. Skovronsky has 14 years of service with Lilly.
- Anne E. White
Anne E. White自2018年9月起担任礼来肿瘤学高级副总裁兼总裁。
Anne E. White,Executive Vice President and President, Lilly Neuroscience (since 2021). Previously, Ms. White held various leadership roles with Lilly, including senior vice president and president, Lilly Oncology, vice president of Portfolio Management, Chorus, and Next Generation Research and Development. Ms. White has 29 years of service with Lilly.- Anne E. White自2018年9月起担任礼来肿瘤学高级副总裁兼总裁。
- Anne E. White,Executive Vice President and President, Lilly Neuroscience (since 2021). Previously, Ms. White held various leadership roles with Lilly, including senior vice president and president, Lilly Oncology, vice president of Portfolio Management, Chorus, and Next Generation Research and Development. Ms. White has 29 years of service with Lilly.
- Anat Hakim
Anat Hakim,自2020年2月以来担任高级副总裁兼总法律顾问。在加入礼来之前,Hakim女士曾是一家管理型护理公司的执行副总裁,总法律顾问和Wellcare Health Plans秘书。 在加入Wellcare之前,她曾在卫生保健公司Abbott Laboratories担任部门副总裁兼副总法律顾问。
Anat Hakim,Executive Vice President, General Counsel and Secretary (since 2020). Prior to joining Lilly, Ms. Hakim was senior vice president, general counsel and secretary of WellCare Health Plans, Inc. (WellCare) from 2016 to 2018, and executive vice president, general counsel and secretary of WellCare from 2018 to 2020. Prior to joining WellCare, she served as divisional vice president and associate general counsel of intellectual property litigation at Abbott Laboratories from 2010 to 2013 and divisional vice president and associate general counsel of litigation from 2013 to 2016. Ms. Hakim has five years of service with Lilly.- Anat Hakim,自2020年2月以来担任高级副总裁兼总法律顾问。在加入礼来之前,Hakim女士曾是一家管理型护理公司的执行副总裁,总法律顾问和Wellcare Health Plans秘书。 在加入Wellcare之前,她曾在卫生保健公司Abbott Laboratories担任部门副总裁兼副总法律顾问。
- Anat Hakim,Executive Vice President, General Counsel and Secretary (since 2020). Prior to joining Lilly, Ms. Hakim was senior vice president, general counsel and secretary of WellCare Health Plans, Inc. (WellCare) from 2016 to 2018, and executive vice president, general counsel and secretary of WellCare from 2018 to 2020. Prior to joining WellCare, she served as divisional vice president and associate general counsel of intellectual property litigation at Abbott Laboratories from 2010 to 2013 and divisional vice president and associate general counsel of litigation from 2013 to 2016. Ms. Hakim has five years of service with Lilly.
- Patrik Jonsson
Patrik Jonsson自2019年9月以来,生物医学高级副总裁兼总裁。
Patrik Jonsson,Executive Vice President and President, Lilly Cardiometabolic Health and President, Lilly USA (since 2024). Mr. Jonsson has held various leadership roles with Lilly, including, most recently, as Executive Vice President and President, Lilly Immunology and Lilly USA, and Chief Customer Officer. Previously, he served as senior vice president and president, Lilly Bio-Medicines and president and general manager, Lilly Japan. Mr. Jonsson has 34 years of service with Lilly.- Patrik Jonsson自2019年9月以来,生物医学高级副总裁兼总裁。
- Patrik Jonsson,Executive Vice President and President, Lilly Cardiometabolic Health and President, Lilly USA (since 2024). Mr. Jonsson has held various leadership roles with Lilly, including, most recently, as Executive Vice President and President, Lilly Immunology and Lilly USA, and Chief Customer Officer. Previously, he served as senior vice president and president, Lilly Bio-Medicines and president and general manager, Lilly Japan. Mr. Jonsson has 34 years of service with Lilly.
- Ilya Yuffa
Ilya Yuffa自2020年起担任礼来生物医药公司高级副总裁兼总裁。此前,Yuffa先生曾在礼来担任过各种领导职务,包括U.S. Diabetes副总裁,意大利中心总经理,以及2014年以来的全球道德和合规官副总裁。Yuffa先生在礼来服务了24年。
Ilya Yuffa,Executive Vice President and President, Lilly International (since 2021). Previously, Mr. Yuffa held various leadership roles with Lilly, including senior vice president and president, Lilly Bio-Medicines, vice president of U.S. Diabetes, general manager of Italy Hub, and vice president, global ethics and compliance officer. Mr. Yuffa has 28 years of service with Lilly.- Ilya Yuffa自2020年起担任礼来生物医药公司高级副总裁兼总裁。此前,Yuffa先生曾在礼来担任过各种领导职务,包括U.S. Diabetes副总裁,意大利中心总经理,以及2014年以来的全球道德和合规官副总裁。Yuffa先生在礼来服务了24年。
- Ilya Yuffa,Executive Vice President and President, Lilly International (since 2021). Previously, Mr. Yuffa held various leadership roles with Lilly, including senior vice president and president, Lilly Bio-Medicines, vice president of U.S. Diabetes, general manager of Italy Hub, and vice president, global ethics and compliance officer. Mr. Yuffa has 28 years of service with Lilly.
- Edgardo Hernandez
Edgardo Hernandez,高级副总裁兼总裁,制造业务自2021。此前,Hernandez曾在礼来担任多个领导职务,包括负责全球肠外药品、递送设备和区域制造的高级副总裁,以及负责费格谢姆运营的副总裁。Hernandez先生在礼来服务了17年。
Edgardo Hernandez,Executive Vice President and President, Manufacturing Operations (since 2021). Previously, Mr. Hernandez held various leadership roles with Lilly, including senior vice president, global parenteral drug product, delivery devices and regional manufacturing, and vice president, Fegersheim operations. Mr. Hernandez has 20 years of service with Lilly.- Edgardo Hernandez,高级副总裁兼总裁,制造业务自2021。此前,Hernandez曾在礼来担任多个领导职务,包括负责全球肠外药品、递送设备和区域制造的高级副总裁,以及负责费格谢姆运营的副总裁。Hernandez先生在礼来服务了17年。
- Edgardo Hernandez,Executive Vice President and President, Manufacturing Operations (since 2021). Previously, Mr. Hernandez held various leadership roles with Lilly, including senior vice president, global parenteral drug product, delivery devices and regional manufacturing, and vice president, Fegersheim operations. Mr. Hernandez has 20 years of service with Lilly.
- Diogo Rau
Diogo Rau,高级副总裁兼首席信息和数字军官自2021。在加入礼来之前,Rau先生是苹果公司零售和在线商店信息系统和技术的高级主管,从2011到2021。在苹果任职之前,他曾在麦肯锡公司担任合伙人。
Diogo Rau,Executive Vice President and Chief Information and Digital Officer (since 2021). Prior to joining Lilly, Mr. Rau was senior director of information systems and technology for retail and online stores of Apple Inc. from 2011 to 2021. Prior to his tenure at Apple, he served as a partner at McKinsey & Company. Mr. Rau has four years of service with Lilly.- Diogo Rau,高级副总裁兼首席信息和数字军官自2021。在加入礼来之前,Rau先生是苹果公司零售和在线商店信息系统和技术的高级主管,从2011到2021。在苹果任职之前,他曾在麦肯锡公司担任合伙人。
- Diogo Rau,Executive Vice President and Chief Information and Digital Officer (since 2021). Prior to joining Lilly, Mr. Rau was senior director of information systems and technology for retail and online stores of Apple Inc. from 2011 to 2021. Prior to his tenure at Apple, he served as a partner at McKinsey & Company. Mr. Rau has four years of service with Lilly.
- Eric Dozier
Eric Dozier,人力资源和多样性执行副总裁(自2022年起)。此前,他曾担任Lilly的各种领导职务,包括Loxo@Lilly的高级副总裁、首席商务官、副总裁、全球道德和合规官。他在Lilly公司工作了25年。
Eric Dozier,Executive Vice President, Chief People Officer (since 2022). Previously, Mr. Dozier held various leadership roles with Lilly, including senior vice president, chief commercial officer for Loxo@Lilly, and vice president, global ethics and compliance officer. Mr. Dozier has 27 years of service with Lilly.- Eric Dozier,人力资源和多样性执行副总裁(自2022年起)。此前,他曾担任Lilly的各种领导职务,包括Loxo@Lilly的高级副总裁、首席商务官、副总裁、全球道德和合规官。他在Lilly公司工作了25年。
- Eric Dozier,Executive Vice President, Chief People Officer (since 2022). Previously, Mr. Dozier held various leadership roles with Lilly, including senior vice president, chief commercial officer for Loxo@Lilly, and vice president, global ethics and compliance officer. Mr. Dozier has 27 years of service with Lilly.
- Lucas Montarce
Lucas Montarce,自2001年加入Lilly以来,他担任过一系列财务领导职务。最近,他于2024年担任西班牙,葡萄牙和Greece hub的总裁兼总经理。在此之前,他曾担任Lilly Research Laboratories的集团副总裁、财务总监兼首席财务官(2021年以来)。他在Lilly担任过的其他领导职务包括:副总裁,财务和首席财务官Lilly International;Elanco Health的财务副总裁和全球首席财务官。
Lucas Montarce,Executive Vice President and Chief Financial Officer (since 2024). Most recently, Mr. Montarce served as the president and general manager of Lilly's Spain, Portugal, and Greece hub, a position he assumed in 2024. Previously Mr. Montarce was group vice president, controller and chief financial officer of Lilly Research Laboratories, vice president, finance and chief financial officer, Lilly International, and vice president, finance and global chief financial officer, Elanco Health. Mr. Montarce has 23 years of service with Lilly.- Lucas Montarce,自2001年加入Lilly以来,他担任过一系列财务领导职务。最近,他于2024年担任西班牙,葡萄牙和Greece hub的总裁兼总经理。在此之前,他曾担任Lilly Research Laboratories的集团副总裁、财务总监兼首席财务官(2021年以来)。他在Lilly担任过的其他领导职务包括:副总裁,财务和首席财务官Lilly International;Elanco Health的财务副总裁和全球首席财务官。
- Lucas Montarce,Executive Vice President and Chief Financial Officer (since 2024). Most recently, Mr. Montarce served as the president and general manager of Lilly's Spain, Portugal, and Greece hub, a position he assumed in 2024. Previously Mr. Montarce was group vice president, controller and chief financial officer of Lilly Research Laboratories, vice president, finance and chief financial officer, Lilly International, and vice president, finance and global chief financial officer, Elanco Health. Mr. Montarce has 23 years of service with Lilly.
- Melissa Seymour
Melissa Seymour,全球质量执行副总裁(自2024年起)。在加入礼来公司之前,她从2022年到2024年担任Bristol Myers Squibb的首席质量官。在加入Bristol Myers Squibb之前,她也是Biogen的首席质量官。西摩女士在礼来公司工作了一年。
Melissa Seymour,Executive Vice President, Global Quality (since 2024). Prior to joining Lilly, Ms. Seymour was the chief quality officer for Bristol Myers Squibb from 2022 to 2024. Before joining Bristol Myers Squibb, Ms. Seymour was also the chief quality officer at Biogen. Ms. Seymour has one year of service with Lilly.- Melissa Seymour,全球质量执行副总裁(自2024年起)。在加入礼来公司之前,她从2022年到2024年担任Bristol Myers Squibb的首席质量官。在加入Bristol Myers Squibb之前,她也是Biogen的首席质量官。西摩女士在礼来公司工作了一年。
- Melissa Seymour,Executive Vice President, Global Quality (since 2024). Prior to joining Lilly, Ms. Seymour was the chief quality officer for Bristol Myers Squibb from 2022 to 2024. Before joining Bristol Myers Squibb, Ms. Seymour was also the chief quality officer at Biogen. Ms. Seymour has one year of service with Lilly.